How We Lead – Perspectives from Two Key Biotechnology Hubs in North America

March 8, 2021 11:30 AM - 1:15 PM

Webinar, click "live-stream" button to view

Add to Calendar 3/8/2021 11:30:00 AM 3/8/2021 1:15:00 PM How We Lead – Perspectives from Two Key Biotechnology Hubs in North America

Join us on International Women’s Day, March 8, 2021, when WIB-Greater Montreal and WIB-Greater Boston will present a joint event with BIOQuébec and MassBio.

BIOQuébec is committed to supporting Québec’s biotechnology and life sciences industry. MassBio’s mission is to advance Massachusetts’ leadership in the life sciences and each is dedicated to improving healthcare and quality of life. Join the discussion of the landscape in Quebec and Massachusetts and biotech leaders’ perspectives on challenges/obstacles faced, leadership styles, where do we want to be, and how do we get there.

The event will be facilitated by journalist-columnist Tasha Kheiriddin with panelists from Québec: Anie Perrault, executive director BIOQuébec, Clarissa Desjardins, founder and former CEO, Clementia (now Ipsen), and Nadine Beauger, President & CEO, IRICOR and from Massachusetts: Kendalle Burin O’Connell, President & COO MassBio, Ramani Varanasi- President & CEO of X-Biotix Therapeutics, and Liang Schweizer- CEO & CSO of HiFiBiO Therapeutics.

PLEASE NOTE: You will be redirected to the Women In Bio event page by clicking, "Register Now." This event requires you to sign-in to receive a personalized link to the webinar. Please select “sign-in” and then choose “non-member.” The event is free for all MassBio members.

Disclaimer: This event may be recorded. There is a possibility your image and/or voice may be a part of that recording. If you are uncomfortable, please be sure to turn off your webcam.

Webinar, click "live-stream" button to view
Co-Founder, President & CEO,
Ms. Varanasi is a co-founder, President and CEO of X-Biotix Therapeutics, a biopharma company based in the Boston area and focused on the discovery and development of novel antibiotics to combat the ever-increasing global issue of multi-drug resistance caused by “Superbugs”. Being attracted to mission-driven initiatives, Ramani has operated with an entrepreneurial vision and passion for launching, building and being part of successful organizations by integrating research and business strategies focused on innovative medicines and solutions having a global impact. She is an accomplished business executive, with over 20 years of biopharmaceutical industry experience and a distinguished track record in structuring, negotiating and executing successful strategic alliances, licensing agreements and M&A transactions as well as providing business development, management and strategic leadership to organizations. She has held Research and senior level positions in Business & Corporate Development including at Merck, Millennium (now Takeda), Momenta, and Checkmate Pharmaceuticals, to name a few. Over the course of her career, Ramani has been involved in the formation of strategic partnerships with companies and research organizations globally, including in emerging markets such as Asia - and continues to have a keen interest in bridging the research and business gap and fostering collaboration between enterprises in this global marketplace. Her broad experience in the areas of early stage company formation and financing, including dilutive and non-diluting funding initiatives, has enabled her to execute deals with total value in excess of several billion dollars. Ramani holds a B.Sc. and a M.Sc. from McGill University in Microbiology & Immunology and Biochemistry, respectfully, and an MBA in General Strategy from Northeastern University.